Kornitzer Capital Management Inc. KS Increases Position in Simulations Plus, Inc. $SLP

Kornitzer Capital Management Inc. KS increased its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 121.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 51,000 shares of the technology company’s stock after acquiring an additional 28,000 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Simulations Plus were worth $769,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Royal Bank of Canada increased its holdings in Simulations Plus by 26.6% during the 1st quarter. Royal Bank of Canada now owns 114,885 shares of the technology company’s stock worth $2,817,000 after purchasing an additional 24,132 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Simulations Plus by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock worth $233,000 after buying an additional 390 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Simulations Plus in the first quarter worth $255,000. Woodline Partners LP raised its holdings in Simulations Plus by 32.1% in the first quarter. Woodline Partners LP now owns 13,239 shares of the technology company’s stock valued at $325,000 after acquiring an additional 3,220 shares in the last quarter. Finally, Values First Advisors Inc. raised its holdings in Simulations Plus by 46.4% in the second quarter. Values First Advisors Inc. now owns 57,372 shares of the technology company’s stock valued at $1,001,000 after acquiring an additional 18,184 shares in the last quarter. Institutional investors and hedge funds own 78.08% of the company’s stock.

Simulations Plus Stock Performance

Shares of SLP opened at $18.63 on Thursday. The firm has a fifty day moving average of $19.02 and a 200-day moving average of $16.47. The company has a market cap of $375.39 million, a price-to-earnings ratio of -5.82 and a beta of 1.09. Simulations Plus, Inc. has a 1 year low of $12.39 and a 1 year high of $37.67.

Simulations Plus (NASDAQ:SLP) last announced its earnings results on Thursday, January 8th. The technology company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.05). The business had revenue of $18.42 million for the quarter, compared to the consensus estimate of $18.05 million. Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. During the same period in the previous year, the firm earned $0.17 EPS. Analysts predict that Simulations Plus, Inc. will post 1.09 EPS for the current year.

Wall Street Analyst Weigh In

SLP has been the subject of several recent analyst reports. TD Cowen reissued a “hold” rating on shares of Simulations Plus in a report on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Simulations Plus in a research report on Wednesday, October 8th. Citigroup reissued a “market perform” rating on shares of Simulations Plus in a report on Tuesday, January 6th. KeyCorp reaffirmed a “sector weight” rating on shares of Simulations Plus in a report on Wednesday, October 29th. Finally, Zacks Research upgraded Simulations Plus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $25.00.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.